Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection

Chidchamai Kewcharoenwong, Darawan Rinchai, Kusumawadee Utispan, Duangchan Suwannasaen, Gregory J. Bancroft, Manabu Ato, Ganjana Lertmemongkolchai

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei. Our previous study has shown that polymorphonuclear neutrophils (PMNs) from diabetic subjects exhibited decreased functions in response to B. pseudomallei. Here we investigated the mechanisms regulating cytokine secretion of PMNs from diabetic patients which might contribute to patient susceptibility to bacterial infections. Purified PMNs from diabetic patients who had been treated with glibenclamide (an ATP-sensitive potassium channel blocker for anti-diabetes therapy), showed reduction of interleukin (IL)-1β and IL-8 secretion when exposed to B. pseudomallei. Additionally, reduction of these pro-inflammatory cytokines occurred when PMNs from diabetic patients were treated in vitro with glibenclamide. These findings suggest that glibenclamide might be responsible for the increased susceptibility of diabetic patients, with poor glycemic control, to bacterial infections as a result of its effect on reducing IL-1β production by PMNs.

Original languageEnglish
Article number3363
JournalScientific Reports
Volume3
DOIs
Publication statusPublished - 28 Nov 2013
Externally publishedYes

Fingerprint

Glyburide
Bacterial Infections
Burkholderia pseudomallei
Neutrophils
Cytokines
Interleukin-1
Potassium Channel Blockers
Melioidosis
KATP Channels
Interleukin-8
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • General
  • Medicine(all)

Cite this

Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. / Kewcharoenwong, Chidchamai; Rinchai, Darawan; Utispan, Kusumawadee; Suwannasaen, Duangchan; Bancroft, Gregory J.; Ato, Manabu; Lertmemongkolchai, Ganjana.

In: Scientific Reports, Vol. 3, 3363, 28.11.2013.

Research output: Contribution to journalArticle

Kewcharoenwong, Chidchamai ; Rinchai, Darawan ; Utispan, Kusumawadee ; Suwannasaen, Duangchan ; Bancroft, Gregory J. ; Ato, Manabu ; Lertmemongkolchai, Ganjana. / Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. In: Scientific Reports. 2013 ; Vol. 3.
@article{2c2f27b1e758457ca03c78640b1c4087,
title = "Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection",
abstract = "Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei. Our previous study has shown that polymorphonuclear neutrophils (PMNs) from diabetic subjects exhibited decreased functions in response to B. pseudomallei. Here we investigated the mechanisms regulating cytokine secretion of PMNs from diabetic patients which might contribute to patient susceptibility to bacterial infections. Purified PMNs from diabetic patients who had been treated with glibenclamide (an ATP-sensitive potassium channel blocker for anti-diabetes therapy), showed reduction of interleukin (IL)-1β and IL-8 secretion when exposed to B. pseudomallei. Additionally, reduction of these pro-inflammatory cytokines occurred when PMNs from diabetic patients were treated in vitro with glibenclamide. These findings suggest that glibenclamide might be responsible for the increased susceptibility of diabetic patients, with poor glycemic control, to bacterial infections as a result of its effect on reducing IL-1β production by PMNs.",
author = "Chidchamai Kewcharoenwong and Darawan Rinchai and Kusumawadee Utispan and Duangchan Suwannasaen and Bancroft, {Gregory J.} and Manabu Ato and Ganjana Lertmemongkolchai",
year = "2013",
month = "11",
day = "28",
doi = "10.1038/srep03363",
language = "English",
volume = "3",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection

AU - Kewcharoenwong, Chidchamai

AU - Rinchai, Darawan

AU - Utispan, Kusumawadee

AU - Suwannasaen, Duangchan

AU - Bancroft, Gregory J.

AU - Ato, Manabu

AU - Lertmemongkolchai, Ganjana

PY - 2013/11/28

Y1 - 2013/11/28

N2 - Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei. Our previous study has shown that polymorphonuclear neutrophils (PMNs) from diabetic subjects exhibited decreased functions in response to B. pseudomallei. Here we investigated the mechanisms regulating cytokine secretion of PMNs from diabetic patients which might contribute to patient susceptibility to bacterial infections. Purified PMNs from diabetic patients who had been treated with glibenclamide (an ATP-sensitive potassium channel blocker for anti-diabetes therapy), showed reduction of interleukin (IL)-1β and IL-8 secretion when exposed to B. pseudomallei. Additionally, reduction of these pro-inflammatory cytokines occurred when PMNs from diabetic patients were treated in vitro with glibenclamide. These findings suggest that glibenclamide might be responsible for the increased susceptibility of diabetic patients, with poor glycemic control, to bacterial infections as a result of its effect on reducing IL-1β production by PMNs.

AB - Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei. Our previous study has shown that polymorphonuclear neutrophils (PMNs) from diabetic subjects exhibited decreased functions in response to B. pseudomallei. Here we investigated the mechanisms regulating cytokine secretion of PMNs from diabetic patients which might contribute to patient susceptibility to bacterial infections. Purified PMNs from diabetic patients who had been treated with glibenclamide (an ATP-sensitive potassium channel blocker for anti-diabetes therapy), showed reduction of interleukin (IL)-1β and IL-8 secretion when exposed to B. pseudomallei. Additionally, reduction of these pro-inflammatory cytokines occurred when PMNs from diabetic patients were treated in vitro with glibenclamide. These findings suggest that glibenclamide might be responsible for the increased susceptibility of diabetic patients, with poor glycemic control, to bacterial infections as a result of its effect on reducing IL-1β production by PMNs.

UR - http://www.scopus.com/inward/record.url?scp=84889584784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889584784&partnerID=8YFLogxK

U2 - 10.1038/srep03363

DO - 10.1038/srep03363

M3 - Article

VL - 3

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 3363

ER -